Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 10/20 | 0.61 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.57 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21882810 | 0.94 | NT5E (0.54) | NT5ERNASELDOT1LDNPH1TAS1R3 | |
| SCHEMBL21839485 | 0.90 | NT5E (0.64) | NT5ERNASELDNPH1TAS1R3TAS1R1 | |
| SCHEMBL30394278 | 0.90 | NT5E (0.64) | NT5ERNASELDNPH1TAS1R3TAS1R1 | |
| SCHEMBL21839573 | 0.89 | NT5E (0.63) | NT5ERNASELDNPH1TAS1R3TAS1R1 | |
| SCHEMBL30394900 | 0.87 | NT5E (0.77) | NT5ERNASELDOT1LDNPH1TAS1R3 | |
| SCHEMBL21839880 | 0.87 | NT5E (0.77) | NT5ERNASELDOT1LDNPH1TAS1R3 | |
| SCHEMBL6663002 | 0.86 | ADORA3 (0.71) | DOT1LADORA3 | |
| SCHEMBL6662994 | 0.86 | ADORA3 (0.71) | DOT1LADORA3 | |
| SCHEMBL21839481 | 0.85 | NT5E (0.77) | NT5ETAS1R3TAS1R1ADORA3 | |
| SCHEMBL21839592 | 0.85 | P2RX3 (0.61) | NT5ERNASELDNPH1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885RNASEL 384/4885DOT1L 3158/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885RNASEL 217/4885DOT1L 2237/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885RNASEL 384/4885DOT1L 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.